|
ATCC
human melanoma cell line a375 ![]() Human Melanoma Cell Line A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human melanoma cell line a375/product/ATCC Average 99 stars, based on 1 article reviews
human melanoma cell line a375 - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
human ocular choroidal melanoma cell line ![]() Human Ocular Choroidal Melanoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human ocular choroidal melanoma cell line/product/ATCC Average 97 stars, based on 1 article reviews
human ocular choroidal melanoma cell line - by Bioz Stars,
2026-05
97/100 stars
|
Buy from Supplier |
|
ATCC
human melanoma cells ![]() Human Melanoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human melanoma cells/product/ATCC Average 99 stars, based on 1 article reviews
human melanoma cells - by Bioz Stars,
2026-05
99/100 stars
|
Buy from Supplier |
|
ATCC
a375 m2 ![]() A375 M2, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/a375 m2/product/ATCC Average 95 stars, based on 1 article reviews
a375 m2 - by Bioz Stars,
2026-05
95/100 stars
|
Buy from Supplier |
|
ATCC
a375p ![]() A375p, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/a375p/product/ATCC Average 95 stars, based on 1 article reviews
a375p - by Bioz Stars,
2026-05
95/100 stars
|
Buy from Supplier |
|
ATCC
cancer cell lines a375 s2 ![]() Cancer Cell Lines A375 S2, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cancer cell lines a375 s2/product/ATCC Average 94 stars, based on 1 article reviews
cancer cell lines a375 s2 - by Bioz Stars,
2026-05
94/100 stars
|
Buy from Supplier |
|
ATCC
a375 ![]() A375, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/a375/product/ATCC Average 92 stars, based on 1 article reviews
a375 - by Bioz Stars,
2026-05
92/100 stars
|
Buy from Supplier |
|
ATCC
a375 ma1 cells ![]() A375 Ma1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/a375 ma1 cells/product/ATCC Average 93 stars, based on 1 article reviews
a375 ma1 cells - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
ATCC
375 cell line ![]() 375 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/375 cell line/product/ATCC Average 90 stars, based on 1 article reviews
375 cell line - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
ATCC
kras mutant cell lines ![]() Kras Mutant Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/kras mutant cell lines/product/ATCC Average 93 stars, based on 1 article reviews
kras mutant cell lines - by Bioz Stars,
2026-05
93/100 stars
|
Buy from Supplier |
|
ATCC
brafv600e nrasq61k ![]() Brafv600e Nrasq61k, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/brafv600e nrasq61k/product/ATCC Average 92 stars, based on 1 article reviews
brafv600e nrasq61k - by Bioz Stars,
2026-05
92/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Journal for Immunotherapy of Cancer
Article Title: AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
doi: 10.1136/jitc-2025-013305
Figure Lengend Snippet: Prediction of ICI outcomes using the FD.sig model with IFN-γ as a key factor. ( A ) Flowchart of constructing FD.model for ICI prediction response. ( B ) The volcano plot of FD.score between tumor and normal tissues in TCGA data; ( C ) Survival analysis of FD.score in TCGA-SKCM. ( D ) ROC curves of eight machine-learning methods in testing set. ( E ) AUCs of eight methods in training and testing sets. ( F ) Comparison of AUCs between FD.sig and other signatures in training and testing sets. ( G ) Comparison of AUCs between FD.sig and other signatures in each cohort. ( H ) The importance ranking of genes in FD.model. ( I ) Comparison of IFNG expression on T cells between responder, non-responder and treatment-naïve in GSE115978 . ( J–K ) Cell viability of A375 cells and H1299 cells treated with different concentrations of RSL3/RSL3+Fer-1 for 24 hours after IFN-γ incubation for 0–72 hours (n=3), IFN-γ: 100 mg/mL, Fer-1: 1 µM. ( L–M ) Relative ROS level of A375 ( L ) and H1299 cells ( M ) treated with RSL3/RSL3+Fer-1 for 3 hours after IFN-γ incubation for 48 hours (n=3), IFN-γ: 60 mg/mL, RSL3: 500 nM, Fer-1: 1 µM. AUC, area under the receiver operating characteristic curve; BLCA, bladder urothelial carcinoma; BRCA, breast cancer; CRAD, colorectal adenocarcinoma; FD.model, ferroptosis-based machine learning model; FD.sig, ferroptosis-driver signature; HNSC, head and neck squamous carcinoma; ICI, immune checkpoint inhibitor; IFN, interferon; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NR, non-responders; OS, overall survival; PRAD, prostate adenocarcinoma; R, responders; ROC, receiver operating characteristic; ROS, reactive oxygen species; scRNA-seq, single-cell RNA sequencing; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma.
Article Snippet:
Techniques: Comparison, Expressing, Incubation, Single Cell, RNA Sequencing
Journal: Journal for Immunotherapy of Cancer
Article Title: AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
doi: 10.1136/jitc-2025-013305
Figure Lengend Snippet: IFN-γ induces the sensitivity of ferroptosis through lipid remodeling. ( A–B ) Ratios of different lipids in A375 cells and H1299 cells after IFN-γ incubation for different times, IFN-γ: 60 mg/mL. ( C ) Differential analysis of free fatty acids compared the control group with IFN-γ incubation groups in A375 cells and H1299 cells, IFN-γ: 60 mg/mL. ( D ) Ratios of ether lipids and ester lipids in H1299 cells after IFN-γ incubation, IFN-γ: 60 mg/mL. ( E–F ) Heatmap of ether-PC and ether-PE in A375 ( E ) and H1299 cells ( F ) after IFN-γ incubation, IFN-γ: 60 mg/mL. FA, fatty acyls; GL, glycerolipids; GP, glycerophospholipids; IFN, interferon; MUFA, monounsaturated fatty acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PR, prenol lipids; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; SP, sphingolipids; ST, sterol lipids.
Article Snippet:
Techniques: Incubation, Control
Journal: Journal for Immunotherapy of Cancer
Article Title: AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
doi: 10.1136/jitc-2025-013305
Figure Lengend Snippet: IFN-γ induces the sensitivity of ferroptosis through ether lipids. ( A, C ) Volcano plot of ether-PC and ether-PE compared the control group with IFN-γ incubation groups in A375 cells and H1299 cells, IFN-γ: 60 mg/mL. ( B, D ) Intersection Venn diagram of differential lipids in A375 cells and H1299 cells. ( E–J ) Cell viability of A375 and H1299 cells treated with RSL3/RSL3+Fer-1 for 12 hours after incubation with indicated phospholipids, including PC 18_18:1 ( E ), PE 18_18:1 ( F ), PC 18_20:4 ( G ), PE 18_20:4 ( H ), PC 18_22:6 ( I ), PE 18_22:6 ( J ), phospholipids: 25 µM, Fer-1: 1 µm. ( K ) Comparison of lipid metabolism pathways with transcriptome data among groups with different IFN-γ incubation times in A375 cells and H1299 cells, IFN-γ: 60 mg/mL. IFN, interferon; PC, phosphatidylcholine; PE, phosphatidylethanolamine.
Article Snippet:
Techniques: Control, Incubation, Comparison
Journal: Journal for Immunotherapy of Cancer
Article Title: AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
doi: 10.1136/jitc-2025-013305
Figure Lengend Snippet: IFN-γ alters the ether lipid metabolism via the IRF1-AGPAT3 axis. ( A ) Schematic summarizing the PUFA-ePLs biosynthesis pathway and their contribution to ferroptosis susceptibility. ( B ) Heatmap of different groups on the expression of specific genes in A375 cells and H1299 cells. ( C ) Representative western blot for AGPS, AGPAT3 and GNPAT in A375 cells and H1299 cells after IFN-γ incubation, IFN-γ: 60 mg/mL. ( D ) Cell viability of different groups treated with different concentrations of RSL3/RSL3+Fer-1 for 24 hours after IFN-γ incubation for 48 hours (n=3), IFN-γ: 100 mg/mL, Fer-1: 1 µM. ( E ) Relative ROS level of different groups treated with RSL3/RSL3+Fer-1 for 3 hours after IFN-γ incubation for 48 hours (n=3), IFN-γ: 60 mg/mL, RSL3: 500 nM, Fer-1: 1 µM. ( F ) Heatmap of different groups on the expression of IFN-γ downstream transcription factors in A375 cells and H1299 cells. ( G–H ) IRF1 binding sites at the AGPAT3 promoter region in lung cancer cell lines from GSE186168 ChIP-seq data. ( I–J ) The peak of IRF1 binding at the Agpat3 promoter region becomes higher after IFN-γ incubation from GSE201881 ( I ) and GSE141606 ( J ) ChIP-seq data. ( K ) IRF1 binding sites at the AGPAT3 promoter region in A375 from CUT&Tag data. ChIP-seq, chromatin Immunoprecipitation sequencing; CUT&Tag, Cleavage Under Targets and Tagmentation; IFN, interferon; PUFA-ePLs, polyunsaturated ether phospholipids; ROS, reactive oxygen species.
Article Snippet:
Techniques: Expressing, Western Blot, Incubation, Binding Assay, ChIP-sequencing
Journal: Journal for Immunotherapy of Cancer
Article Title: AGPAT3 reshapes tumor cell vulnerability to IFNγ-mediated ferroptosis and enhances immunotherapy efficacy through lipid remodeling
doi: 10.1136/jitc-2025-013305
Figure Lengend Snippet: IFN-γ alters the ether lipid metabolism via the IRF1-AGPAT3 axis. ( A–B ) Changes in ratio of ether lipids and eater lipids in A375 and H1299 cells in NC, sh-AGPAT3 and sh-AGPAT3+IFN-γ group, IFN-γ: 60 mg/mL. ( C–D ) Changes in ratio of different ether lipids in A375 and H1299 cells in NC, sh-AGPAT3 and sh-AGPAT3+IFN-γ group, IFN-γ: 60 mg/mL. ( E–F ) Heatmap of ether-PC and ether-PE in A375 ( E ) and H1299 cells ( F ) in different groups, IFN-γ: 60 mg/mL. IFN, interferon; NC, normal control; PC, phosphatidylcholine; PE, phosphatidylethanolamine.
Article Snippet:
Techniques: Control